Enzyme Inhibitor Market Report 2025

The enzyme inhibitor market size has grown steadily in recent years. It will grow from $183.8 billion in 2024 to $189.26 billion in 2025 at a compound annual growth rate (CAGR) of 3%. The growth in the historic period can be attributed to increased demand for enzyme inhibitors inThe treatment of various diseases, advancements in drug discovery and development, growing prevalence of chronic diseases, increased geriatric population, rising awareness aboutThe benefits of enzyme inhibitors.

The enzyme inhibitor market size is expected to see steady growth in the next few years. It will grow to $226.65 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to growing investment in research and development activities, increasing demand for personalized medicine, rising incidence of chronic diseases in emerging markets, growing demand for enzyme inhibitors in the treatment of cancer, expansion of applications in rare and genetic diseases. Major trends in the forecast period include development of reversible and irreversible enzyme inhibitors, exploration of natural products as sources of enzyme inhibitors, integration of computational methods in enzyme inhibitor discovery, emphasis on personalized dosing and treatment regimens, expansion of enzyme inhibitor applications in oncology and neurodegenerative diseases.

The rise in the incidence of diseases including cancer is expected to propel the growth of the enzyme inhibitor market going forward. Enzymes, such as telomerase, which is active in most tumor cells, are utilized to cure cancers, including leukemia, and also keep healthy adult cells from becoming cancerous. For instance, in January 2022, according to the American Cancer Society, a US-based non-profit healthcare group dedicated to cancer elimination, on average in the US, 1,670 individuals are going to die from cancer every day in 2022, with 1. 9 million cases being diagnosed and 609,360 fatalities. Therefore, the rise in the incidence of diseases such as cancer is driving the demand for the enzyme inhibitor market growth.

The increasing demand for personalized medicine is expected to propel the growth of the enzyme inhibitor market in the coming years. Personalized medicine, additionally referred to as precision medicine, is a health care and treatment method that considers each person's specific diversity in DNA, surroundings, and lifestyle. Enzyme inhibitors are a valuable tool in personalized medicine because they can be adjusted to particular individuals or disease subtypes and have a wide range of applications in personalized medicine, including focused therapy, precision medicine, diagnostics, and drug discovery. For instance, in 2022, according to the Personalized Medicine Coalition, a US-based nonprofit umbrella association for pharmaceuticals, biotechnology, diagnosis, and information technology firms, as well as healthcare providers and payers, personalized medications contributed to 34% of new drug approvals by the US Food and Drug Administration and had been responsible for at least 25% of approvals in each of the previous eight years. Therefore, the increasing demand for personalized medicine is driving the enzyme inhibitor market.

Leading companies in the enzyme inhibitor market are prioritizing innovative therapies, such as selective kinase inhibitors, to enhance treatment options and improve patient outcomes across various diseases. Jaypirca (pirtobrutinib) is a highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor approved by the FDA for treating adult patients with relapsed or refractory mantle cell lymphoma after at least two prior systemic treatments. For example, in January 2023, Loxo Oncology at Lilly, the oncology division of Eli Lilly and Company, a U.S.-based pharmaceutical firm, introduced Jaypirca tablets. It is the first and only non-covalent (reversible) BTK inhibitor approved by the Food and Drug Administration (FDA), a U.S.-based health organization. This approval marks a major breakthrough for patients with mantle cell lymphoma (MCL) who have exhausted current treatment options. Jaypirca offers a novel approach to targeting the BTK pathway, potentially improving outcomes for this patient group.

Major companies operating in the enzyme inhibitor market are focusing on developing innovative products, such as Sotyktu, to better meet the needs of their existing consumers. Sotyktu is an allosteric tyrosine kinase 2 (TYK2) inhibitor drug intended to inhibit or limit the activity of the TYK2 enzyme by attaching to a location on the enzyme other than its active site. For instance, in September 2022, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, announced the approval of Sotyktu, a selective oral allosteric tyrosine kinase 2 (TYK2) inhibitor that is the first of its kind by the U. S. Food and Drug Administration. Sotyktu is a prescription medication authorized for treating people with moderate-to-severe plaque psoriasis who are not candidates for systemic therapy or phototherapy. 1,2 Sotyktu should not be used in conjunction with other strong immunosuppressants. Sotyktu can serve as the new standard of care for oral therapy for persons with moderate-to-severe plaque psoriasis due to its track record of assisting patients in attaining smoother skin in the POETYK PSO clinical study.

In August 2024, Eli Lilly and Company, a U.S.-based pharmaceutical firm, acquired Morphic Holding, Inc. for an undisclosed sum. Through this acquisition, Eli Lilly seeks to expand its therapeutic portfolio in gastroenterology, drive innovation in treatment options for inflammatory bowel disease, bolster its market presence, capitalize on research synergies, and increase patient access to effective therapies. Morphic Holding Inc. is a U.S.-based biopharmaceutical company focused on developing enzyme inhibitors.

Major companies operating in the enzyme inhibitor market include Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, F. Hoffmann-La Roche AG, Pfizer Inc., Takeda Pharmaceutical Company, Merck and Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Cipla USA Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Acellera Ltd., Bioinfogate SL, BioSolveIT GmbH, Dassault Systèmes BIOVIA Corp., ChemAxon Ltd., Cheminformatics Tools and Services LLC, Cresset BioMolecular Discovery Ltd., Dotmatics Limited, Enamine Ltd., Forge Therapeutics Inc., Inte:Ligand GmbH, LeadIT, Molecular Forecaster Inc., Chemical Computing Group Inc., OpenEye Scientific Software Inc.

Enzyme inhibitor refers to a chemical that inhibits an enzyme's activity. Enzymes participate in a variety of cell processes, including cell signaling, growth, and division, as well as accelerating chemical reactions in the body. Enzymes help to speed up chemical reactions in the body and take part in many cell functions, including cell signaling, growth, and division.

The main types of enzyme inhibitors are proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, aromatase inhibitors, kinase inhibitors, neuraminidase inhibitors, statins, and other types. Proton pump inhibitors refer to medicines that work by decreasing the amount of stomach acid made by glands in the lining of the stomach. The various disease indications include chronic obstructive pulmonary disorders, cardiovascular disease, gastrointestinal disorders, arthritis, inflammatory diseases, and others. The enzyme inhibitors are applicable in chemotherapy, antibiotics, pesticides, cardiovascular treatments, and others and are used in pharmaceuticals, biotechnology, food and beverage, and other end users.

The enzyme inhibitors market research report is one of a series of new reports that provides enzyme inhibitors market statistics, including enzyme inhibitors industry global market size, regional shares, competitors with an enzyme inhibitors market share, detailed enzyme inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the enzyme inhibitors industry. This enzyme inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the enzyme inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enzyme inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the enzyme inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The enzyme inhibitor market consists of sales of competitive, noncompetitive, and uncompetitive inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.